Bluefish receives first order from Iraq

New partnership established for Iraqi market

Since last year, Bluefish has actively been seeking opportunities to increase revenues in the short- to mid-term, both in existing markets but also in markets outside Europe by entering into partnerships with local companies that take the main responsibility for marketing and distribution as well as assume the inventory risk.

The first order received from our new partner in Iraq has a net sales value equivalent of approximately SEK 11 million. Goods will be delivered and corresponding net sales will be accounted for during the second half of 2014.

Further, Bluefish has been approved by the Iraqi Ministry of Health and has received authorization to conduct pharmaceutical activities, which also allow Bluefish to participate in local tender processes.

 

For more information, contact

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: susanna.urdmark@bluefishpharma.com

 

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of 80 products and is growing.

www.bluefishpharma.com

About Us

Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of 80 products and is growing. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.

Subscribe

Documents & Links